DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...

The action follows mounting scientific evidence linking the injectable contraceptive medication to an increased risk for meningioma.

Invivyd (IVVD) announced that the U.S. Food and Drug Administration has granted Fast Track designation for VYD2311, an investigational ...

Invivyd shares rose about 2.4% in premarket trading after the company announced that the U.S. Food and Drug Administration has granted Fast Track designation for ...

FDA approves FUROSCIX- for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 ...

Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- ...

Indivior PLC today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...

Intramuscular injection remains a cornerstone of clinical practice, offering rapid drug absorption and efficacy when performed correctly. However, its success is intrinsically linked to precise ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...